

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 January 2006 (26.01.2006)

PCT

(10) International Publication Number
WO 2006/009940 A1

(51) International Patent Classification: **C07C 327/56,**
A61K 31/16, A61P 35/00

[CN/US]; 634 Massachusetts Avenue, Acton, MA 01720 (US).

(21) International Application Number:
PCT/US2005/021642

(74) Agents: **DAVIS, Steven, G.** et al.; Hamilton, Brook, Smith & Reynolds, P.C., 530 Virginia Road, P.O. Box 9133, Concord, MA 01742-9133 (US).

(22) International Filing Date: 20 June 2005 (20.06.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/582,596 23 June 2004 (23.06.2004) US
60/681,368 16 May 2005 (16.05.2005) US

(71) Applicant (for all designated States except US): **SYNTA PHARMACEUTICALS CORP.** [US/US]; 45 Hartwell Avenue, Lexington, MA 02421 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KOSTIK, Elena** [RU/US]; 10 Park Terrace, #B, Arlington, MA 02474 (US). **VAGHEFI, Farid** [US/US]; 14 Marshall Street, Watertown, MA 02472 (US). **LIANG, Guiping** [CN/US]; 26 Minuteman Drive, Concord, MA 01742 (US). **KOYA, Keizo** [JP/US]; 234 Bonad Road, Chestnut Hill, MA 02467 (US). **SUN, Lijun** [CN/US]; 148 Depot Road, Harvard, MA 01451 (US). **TATSUTA, Noriaki** [JP/US]; 60 Fifer lane, Lexington, MA 02420 (US). **CHEN, Shoujun** [US/US]; 19 Dunster Road, Bedford, MA 01730 (US). **INOUE, Takayo** [JP/JP]; 511-12 Omuro, Ami-machi, Inashiki-gun, Ibaraki 300-0303 (JP). **XIA, Zhi-Qiang**

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: BIS(THIO-HYDRAZIDE AMIDE) SALTS FOR TREATMENT OF CANCERS



(57) Abstract: Disclosed are bis(thio-hydrazide amide) disalts, which are represented by Structural Formula (I) Y is a covalent bond or a substituted or unsubstituted straight chained hydrocarbyl group. R₁-R₄ are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R₁ and R₃ taken together with the carbon and nitrogen atoms to which they are bonded, and/or R₂ and R₄ taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. Z is -O or -S. M⁺ is a pharmaceutically acceptable monovalent cation and M²⁺ is a pharmaceutically acceptable divalent cation. Also, disclosed are pharmaceutical compositions comprising a bis(thio-hydrazide amide) disalt described above. Further disclosed are methods of treating a subject with cancer. The methods comprise the step of administering an effective amount of a bis(thio-hydrazide amide) disalt described above.